Enfuvirtide Acetate (T-20)
Alias:Fuzeon
Sequence:CH3CO-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
Cas No. : 159519-65-0
Molecular Formula : C204H301N51O64
Molecular Weight : 4492
Purity (HPLC) : 98.0%min.
Appearance : White to off-white amorphous solid
Single Impurity (HPLC) : 0.5%max
Amino Acid Composition : ±10% of theoretical
Peptide Content (N%) : ≥80.0%
Water Content (Karl Fischer) : ≤8.0%
TrifluoroAcetate Content(HPIC) : ≤12.0%
MS (ESI) : Consistent
Mass Balance : 95.0~105.0%
Grade : Pharmaceutical Grade
Storage: Closed, below 2 ~ 8℃ preservation
Usage : Treatment option for patients suffering from HIV/AIDS.
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. It binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected.
Enfuvirtide (INN) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).
